9th World Conference on Pharmaceutical Science and Drug Manufacturing
01st & 02nd December 2021, Dubai
Theme : Technological Innovations in Drug Discovery
Organized by : Association of Pharmaceutical ResearchAbstract Submission Register
Association of Pharmaceutical Research (APR) organizes the "9th World Conference on Pharmaceutical Science and Drug Manufacturing" on 1st & 2nd December 2021, in Dubai. This conference is a multidisciplinary program with broad participation with members from around the globe focused on learning about pharmaceutical science, research methodologies, formulations, manufacturing, and its advances. We invite all the Speakers and Delegates from all over the world to attend this conference.
It creates a perfect podium for global networking as it brings together renowned speakers and scientists across the globe to the most exciting and memorable scientific event filled with informative and interactive sessions, international workshops, world-class international exhibitions, and poster presentations.
The Pharmaceutical industry has an important role in designing and developing drugs and vaccines. They play a significant role to treat diseases and more importantly to improve the quality of life. APR provides an excellent platform for the interaction between experts in the areas of pharmaceutics, drug delivery, nanomedicine, biotechnology, and nanotechnology around the world and aims in sharing some unique research and translational studies on various advances in the related fields.
This conference open doors for many researchers in academia, clinicians, and industry representatives working in these exciting areas. It is expected to bring together both reputed scientists in advanced stages of their career and young researchers from many related disciplines. This conference expects many ideas to emerge at the interfaces between disciplines aiming to solve the most important problems relating to the health and wellbeing of humanity.
Technology has been a significant driver of advances in drug discovery. Automation, nanofluidics, imaging, software and assay technologies have played a pivotal role in acquiring better data, faster.
The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process.
To summarise new technologies have the potential to open up avenues of development and to identify new drug targets to pursue.